- Home
- OPRX vs IMUX Comparison
OPRX vs IMUX Comparison
Compare OPRX & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | IMUX |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.5M | 152.6M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OPRX | IMUX |
|---|---|---|
| Price | $7.17 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $16.67 | $4.50 |
| AVG Volume (30 Days) | 516.7K | ★ 2.3M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 38.00 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | $26.56 | ★ N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $5.54 | $0.51 |
| 52 Week High | $22.25 | $1.51 |
Technical Indicators
Market Signals| Indicator | OPRX | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 39.28 |
| Support Level | $7.13 | $0.78 |
| Resistance Level | $7.34 | $1.00 |
| Average True Range (ATR) | 0.46 | 0.10 |
| MACD | 0.16 | -0.03 |
| Stochastic Oscillator | 88.37 | 8.45 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.